Our modeling results indicate that standard dosing regimens achieve therapeutically appropriate exposures in Dravet syndrome patients as young as 6 months, supporting the safe and effective use of CLB and STP co-therapy in this population. This evidence concerns the gene CLYBL and Dravet syndrome.